Form 4: Monopar CFO Plans $105K Stock Purchase

Monopar Therapeutics' Chief Financial Officer, Quan Anh Vu, reported a planned acquisition of 1,500 shares of common stock at $69.95 per share under a Rule 10b5-1 plan.

Summary

• Quan Anh Vu, Chief Financial Officer of Monopar Therapeutics (MNPR), reported a planned purchase of company common stock.
• The transaction involves the acquisition of 1,500 shares.
• The purchase price per share is $69.95.
• The total value of the planned acquisition is $104,925 (1,500 shares * $69.95).
• The transaction is scheduled for December 26, 2025.
• This purchase is being made pursuant to a Rule 10b5-1 trading plan.
• Following this transaction, Mr. Vu will beneficially own 1,500 shares of Monopar Therapeutics common stock.

Sentiment

Score: 8

Explanation: The planned insider purchase by the CFO is a strong positive signal, indicating management's confidence in the company's future prospects and potentially its current valuation. This type of transaction, especially under a 10b5-1 plan, suggests a deliberate and strategic investment.

Positives

• A key executive, the Chief Financial Officer, is planning to acquire company stock, signaling confidence in Monopar Therapeutics' future prospects.
• The purchase is being made at a price of $69.95 per share, representing a significant investment by management.
• The transaction is structured under a Rule 10b5-1 plan, indicating a pre-planned, systematic approach to stock acquisition.

Future Outlook

The planned insider purchase by the CFO suggests a positive internal outlook on the company's future performance, as executives typically invest when they anticipate growth or undervaluation.

Industry Context

Insider buying, particularly by a CFO, can be a strong signal of management's belief in the company's value and future within the competitive biotechnology and pharmaceutical industry. Such actions often precede positive developments or reflect a view that the stock is undervalued relative to its peers or future potential.

Related Party Transactions

• Chief Financial Officer Quan Anh Vu's planned acquisition of 1,500 shares of Monopar Therapeutics common stock at $69.95 per share is a related party transaction.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of future stock performance and management's commitment to increasing shareholder value.

Next Steps

• The planned transaction is scheduled to occur on December 26, 2025.

Key Dates

Recommendation

The planned insider purchase by the Chief Financial Officer, a key executive with deep knowledge of the company's financials and strategic direction, signals strong confidence in Monopar Therapeutics' future. Such a significant investment, especially under a pre-planned 10b5-1 arrangement, suggests management believes the stock is currently undervalued or poised for future growth. This action typically serves as a bullish indicator for investors.

Keywords

Monopar Therapeutics, MNPR, Insider Trading, Form 4, Stock Purchase, CFO, Quan Anh Vu, 10b5-1 Plan, Biotechnology, Pharmaceuticals